Pharmacological inhibition of PKR in APPswePS1dE9 mice transiently prevents inflammation at 12 months of age but increases Aβ42 levels in the late stages of the Alzheimer's disease

Current Alzheimer Research

Volumn 9, Issue 3, 2012, Pages 344-360

  Couturier, Julien ^a   Paccalin, Marc ^a,b   Lafay Chebassier, Claire ^a,b   Chalon, Sylvie ^c   Ingrand, Isabelle ^b,d   Pinguet, Jérémy ^e   Pontcharraud, Raymond ^a   Guillard, Olivier ^a,b   Fauconneau, Bernard ^a   Page, Guylène ^a  

^a UNIVERSITÉ DE POITIERS   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c CHRU de Tours   (France)

^d Department of Public Health ^*  (France)

^e SERVICE DE RHUMATOLOGIE   (France)

Author keywords

A 42 load; APPswePS1dE9; Behavioral tests; Inflammation; NF B; PKR

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; PROTEIN KINASE R; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE EXPRESSION; HIPPOCAMPUS; INFLAMMATION; LONG TERM MEMORY; MALE; MEMORY DISORDER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHORT TERM MEMORY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; WESTERN BLOTTING; WORKING MEMORY;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; EIF-2 KINASE; FEMALE; HUMANS; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; UP-REGULATION;

EID: 84860285084     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512800107582     Document Type: Article

References (77)

1. Williams BR. Signal integration via PKR. Sci STKE. 2001;2001(89):re2. Epub 2001/12/26.
2. Garcia MA, Meurs EF, Esteban M. The dsRNA protein kinase PKR: virus and cell control. Biochimie 2007 89(6-7): 799-811. Epub 2007/04/25.
3. Zhang F, Romano PR, Nagamura-Inoue T, Tian B, Dever TE, Mathews MB, et al. Binding of double-stranded RNA to protein kinase PKR is required for dimerization and promotes critical autophosphorylation events in the activation loop. J Biol Chem 276(27): 24946-58 (2001).
4. Galabru J, Hovanessian A. Autophosphorylation of the protein kinase dependent on double-stranded RNA. J Biol Chem 262(32):15538-44. Epub 1987/11/15 (1987).
5. Ung TL, Cao C, Lu J, Ozato K, Dever TE. Heterologous dimerization domains functionally substitute for the doublestranded RNA binding domains of the kinase PKR. EMBO J 20(14): 3728-37 (2001)
6. Koromilas AE, Roy S, Barber GN, Katze MG, Sonenberg N. Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase. Science 257(5077):1685-9 (1992).
7. Meurs EF, Galabru J, Barber GN, Katze MG, Hovanessian AG. Tumor suppressor function of the interferon-induced doublestranded RNA-activated protein kinase. Proc Natl Acad Sci USA 90(1):232-6 (1993)
8. Peters GA, Dickerman B, Sen GC. Biochemical analysis of PKR activation by PACT. Biochemistry 48(31):7441-7 (2009)
9. Lemaire PA, Lary J, Cole JL. Mechanism of PKR activation: dimerization and kinase activation in the absence of doublestranded RNA. J Mol Biol 345(1): 81-90 (2005)
10. Patel CV, Handy I, Goldsmith T, Patel RC. PACT, a stressmodulated cellular activator of interferon-induced double-stranded RNA-activated protein kinase, PKR. J Biol Chem 275(48): 37993-8 (2000)
11. Patel RC, Sen GC. PACT, a protein activator of the interferoninduced protein kinase, PKR. EMBO J 17(15): 4379-90 (1998).
12. Ito T, Yang M, May WS. RAX, a cellular activator for doublestranded RNA-dependent protein kinase during stress signaling. J Biol Chem 274(22):15427-32 (1999).
13. Yang YL, Reis LF, Pavlovic J, Aguzzi A, Schafer R, Kumar A, et al. Deficient signaling in mice devoid of double-stranded RNAdependent protein kinase. EMBO J 14(24): 6095-106 (1995).
14. Horng T, Barton GM, Medzhitov R. TIRAP: an adapter molecule in the Toll signaling pathway. Nat Immunol 2(9):835-41(2001).
15. Takada Y, Ichikawa H, Pataer A, Swisher S, Aggarwal BB. Genetic deletion of PKR abrogates TNF-induced activation of IkappaBalpha kinase, JNK, Akt and cell proliferation but potentiates p44/p42 MAPK and p38 MAPK activation. Oncogene 26(8):1201-12 (2007).
16. Gil J, Garcia MA, Gomez-Puertas P, Guerra S, Rullas J, Nakano H, et al. TRAF family proteins link PKR with NF-kappa B activation. Mol Cell Biol 24(10): 4502-12 (2004).
17. Jiang Z, Zamanian-Daryoush M, Nie H, Silva AM, Williams BR, Li X. Poly(I-C)-induced Toll-like receptor 3 (TLR3)-mediated activation of NFkappa B and MAP kinase is through an interleukin-1 receptor-associated kinase (IRAK)-independent pathway employing the signaling components TLR3-TRAF6-TAK1-TAB2-PKR. J Biol Chem 278(19):16713-9 (2003).
18. Roff M, Thompson J, Rodriguez MS, Jacque JM, Baleux F, Arenzana-Seisdedos F, et al. Role of IkappaBalpha ubiquitination in signal-induced activation of NFkappaB in vivo. J Biol Chem 271(13): 7844-50 (1996).
19. Oeckinghaus A, Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 1(4):a000034 (2009).
20. Salminen A, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T. Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog Neurobiol 87(3):181-94 (2009).
21. Cameron B, Landreth GE. Inflammation, microglia, and Alzheimer's disease. Neurobiol Dis 37(3): 503-9 (2010).
22. Chang RC, Wong AK, Ng HK, Hugon J. Phosphorylation of eukaryotic initiation factor-2alpha (eIF2alpha) is associated with neuronal degeneration in Alzheimer's disease. Neuroreport 13(18): 2429-32 (2002).
23. Suen KC, Yu MS, So KF, Chang RC, Hugon J. Upstream signaling pathways leading to the activation of double-stranded RNAdependent serine/threonine protein kinase in beta-amyloid peptide neurotoxicity. J Biol Chem 278(50): 49819-27 (2003).
24. Peel AL. PKR activation in neurodegenerative disease. J Neuropathol Exp Neurol 63(2): 97-105 (2004).
25. Onuki R, Bando Y, Suyama E, Katayama T, Kawasaki H, Baba T, et al. An RNA-dependent protein kinase is involved in tunicamycin-induced apoptosis and Alzheimer's disease. EMBO J 23(4): 959-68 (2004).
26. Page G, Rioux Bilan A, Ingrand S, Lafay-Chebassier C, Pain S, Perault Pochat MC, et al. Activated double-stranded RNAdependent protein kinase and neuronal death in models of Alzheimer's disease. Neuroscience 139(4):1343-54 (2006).
27. Morel M, Couturier J, Pontcharraud R, Gil R, Fauconneau B, Paccalin M, et al. Evidence of molecular links between PKR and mTOR signalling pathways in Abeta neurotoxicity: role of p53, Redd1 and TSC2. Neurobiol Dis 36(1):151-61 (2009).
28. Couturier J, Morel M, Pontcharraud R, Gontier V, Fauconneau B, Paccalin M, et al. Interaction of double-stranded RNA-dependent protein kinase (PKR) with the death receptor signaling pathway in amyloid beta (Abeta)-treated cells and in APPSLPS1 knock-in mice. J Biol Chem 285(2):1272-82 (2010).
29. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 21(3): 383-421 (2000).
30. Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol 184(1-2): 69-91 (2007).
31. Lee YJ, Han SB, Nam SY, Oh KW, Hong JT. Inflammation and Alzheimer's disease. Arch Pharm Res 33(10): 1539-56 (2010).
32. Reale M, Iarlori C, Feliciani C, Gambi D. Peripheral chemokine receptors, their ligands, cytokines and Alzheimer's disease. J Alzheimers Dis. 2008;14(2):147-59. Epub 2008/06/19.
33. McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 28(5):639-47 (2007).
34. Ruan L, Kang Z, Pei G, Le Y. Amyloid deposition and inflammation in APPswe/PS1dE9 mouse model of Alzheimer's disease. Curr Alzheimer Res 6(6): 531-40 (2009).
35. Couturier J, Paccalin M, Morel M, Terro F, Milin S, Pontcharraud R, et al. Prevention of the beta-amyloid peptide-induced inflammatory process by inhibition of double-stranded RNAdependent protein kinase in primary murine mixed co-cultures. J Neuroinflammation 8: 72 (2011).
36. Couturier J, Page G, Morel M, Gontier C, Lecron JC, Pontcharraud R, et al. Inhibition of Double-Stranded RNA-Dependent Protein Kinase Strongly Decreases Cytokine Production and Release in Peripheral Blood Mononuclear Cells from Patients with Alzheimer's Disease. J Alzheimers Dis 21(4):1217-31 (2010).
37. Burgess BL, McIsaac SA, Naus KE, Chan JY, Tansley GH, Yang J, et al. Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant A beta in plasma. Neurobiol Dis 24(1):114-27 (2006).
38. Cao D, Lu H, Lewis TL, Li L. Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J Biol Chem 282(50): 36275-82 (2007).
39. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1(1): 47-60 (1984).
40. Chavant F, Deguil J, Pain S, Ingrand I, Milin S, Fauconneau B, et al. Imipramine, in part through tumor necrosis factor alpha inhibition, prevents cognitive decline and beta-amyloid accumulation in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 332(2): 505-14. (2010).
41. Sarter M, Bodewitz G, Stephens DN. Attenuation of scopolamineinduced impairment of spontaneous alteration behaviour by antagonist but not inverse agonist and agonist beta-carbolines. Psychopharmacology (Berl) 94(4): 491-5 (1988).
42. Romano PR, Garcia-Barrio MT, Zhang X, Wang Q, Taylor DR, Zhang F, et al. Autophosphorylation in the activation loop is required for full kinase activity in vivo of human and yeast eukaryotic initiation factor 2alpha kinases PKR and GCN2. Mol Cell Biol 18(4): 2282-97 (1998).
43. Kumar A, Yang YL, Flati V, Der S, Kadereit S, Deb A, et al. Deficient cytokine signaling in mouse embryo fibroblasts with a targeted deletion in the PKR gene: role of IRF-1 and NF-kappaB. EMBO J 16(2): 406-16 (1997).
44. Hu Y, Conway TW. 2-Aminopurine inhibits the double-stranded RNA-dependent protein kinase both in vitro and in vivo. J Interferon Res 13(5): 323-8 (1993).
45. Ingrand S, Barrier L, Lafay-Chebassier C, Fauconneau B, Page G, Hugon J. The oxindole/imidazole derivative C16 reduces in vivo brain PKR activation. FEBS Lett 581(23): 4473-8 (2007).
46. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, et al. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 24(3): 516-24 (2006).
47. Jolivalt CG, Hurford R, Lee CA, Dumaop W, Rockenstein E, Masliah E. Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. Exp Neurol 223(2): 422-31. (2010).
48. Wang X, Zheng W, Xie JW, Wang T, Wang SL, Teng WP, et al. Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model. Mol Neurodegener 5: 46 (2010).
49. Peel AL, Bredesen DE. Activation of the cell stress kinase PKR in Alzheimer's disease and human amyloid precursor protein transgenic mice. Neurobiol Dis 14(1): 52-62 (2003).
50. Zhang X, Luhrs KJ, Ryff KA, Malik WT, Driscoll MJ, Culver B. Suppression of nuclear factor kappa B ameliorates astrogliosis but not amyloid burden in APPswe/PS1dE9 mice. Neuroscience 161(1): 53-8 (2009).
51. Paris D, Ganey NJ, Laporte V, Patel NS, Beaulieu-Abdelahad D, Bachmeier C, et al. Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation 7: 17 (2010).
52. Bonaiuto C, McDonald PP, Rossi F, Cassatella MA. Activation of nuclear factor-kappa B by beta-amyloid peptides and interferongamma in murine microglia. J Neuroimmunol 77(1): 51-6 (1997).
53. Du Y, Chen X, Wei X, Bales KR, Berg DT, Paul SM, et al. NF-(kappa)B mediates amyloid beta peptide-stimulated activity of the human apolipoprotein E gene promoter in human astroglial cells. Brain Res Mol Brain Res 136(1-2): 177-88 (2005).
54. Liu Q, Zhang J, Zhu H, Qin C, Chen Q, Zhao B. Dissecting the signaling pathway of nicotine-mediated neuroprotection in a mouse Alzheimer disease model. FASEB J 21(1): 61-73 (2007).
55. Kassed CA, Butler TL, Navidomskis MT, Gordon MN, Morgan D, Pennypacker KR. Mice expressing human mutant presenilin-1 exhibit decreased activation of NF-kappaB p50 in hippocampal neurons after injury. Brain Res Mol Brain Res 110(1): 152-7 (2003).
56. Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kaltschmidt C. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci USA 94(6): 2642-7 (1997).
57. Ferrer I, Marti E, Lopez E, Tortosa A. NF-kB immunoreactivity is observed in association with beta A4 diffuse plaques in patients with Alzheimer's disease. Neuropathol Appl Neurobiol 24(4): 271-7 (1998).
58. Patel NS, Paris D, Mathura V, Quadros AN, Crawford FC, Mullan MJ. Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease. J Neuroinflammation 2(1): 9 (2005).
59. Jin JJ, Kim HD, Maxwell JA, Li L, Fukuchi K. Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation 5: 23 (2008).
60. Schwab C, Klegeris A, McGeer PL. Inflammation in transgenic mouse models of neurodegenerative disorders. Biochim Biophys Acta 1802(10): 889-902 (2010).
61. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumournecrosis factor-alpha from cells. Nature 385(6618):729-33 (1997).
62. Spaulding CC, Walford RL, Effros RB. Calorie restriction inhibits the age-related dysregulation of the cytokines TNF-alpha and IL-6 in C3B10RF1 mice. Mech Ageing Dev 93(1-3): 87-94. (1997).
63. Njie EG, Boelen E, Stassen FR, Steinbusch HW, Borchelt DR, Streit WJ. Ex vivo cultures of microglia from young and aged rodent brain reveal age-related changes in microglial function. Neurobiol Aging 33(1): 195. e1-12 (2012).
64. Hirohata M, Ono K, Yamada M. Non-steroidal anti-inflammatory drugs as anti-amyloidogenic compounds. Curr Pharm Des 14(30): 3280-94 (2008).
65. Sung S, Yang H, Uryu K, Lee EB, Zhao L, Shineman D, et al. Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. Am J Pathol 165(6):2197-206 (2004).
66. Paris D, Patel N, Quadros A, Linan M, Bakshi P, Ait-Ghezala G, et al. Inhibition of Abeta production by NF-kappaB inhibitors. Neurosci Lett 415(1):11-6 (2007).
67. Buggia-Prevot V, Sevalle J, Rossner S, Checler F. NFkappaBdependent control of BACE1 promoter transactivation by Abeta42. J Biol Chem 283(15):10037-47 (2008).
68. Rossner S, Sastre M, Bourne K, Lichtenthaler SF. Transcriptional and translational regulation of BACE1 expression--implications for Alzheimer's disease. Prog Neurobiol 79(2): 95-111 (2006).
69. Bourne KZ, Ferrari DC, Lange-Dohna C, Rossner S, Wood TG, Perez-Polo JR. Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides. J Neurosci Res 85(6): 1194-204 (2007).
70. Bond M, Chase AJ, Baker AH, Newby AC. Inhibition of transcription factor NF-kappaB reduces matrix metalloproteinase-1,-3 and-9 production by vascular smooth muscle cells. Cardiovasc Res 50(3): 556-65 (2001).
71. Buxbaum JD, Liu KN, Luo Y, Slack JL, Stocking KL, Peschon JJ, et al. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 273(43): 27765-7 (1998).
72. Dominguez D, Tournoy J, Hartmann D, Huth T, Cryns K, Deforce S, et al. Phenotypic and biochemical analyses of BACE1-and BACE2-deficient mice. J Biol Chem 280(35): 30797-806 (2005).
73. Scullion GA, Kendall DA, Marsden CA, Sunter D, Pardon MC. Chronic treatment with the alpha(2)-adrenoceptor antagonist fluparoxan prevents age-related deficits in spatial working memory in APPxPS1 transgenic mice without altering beta-amyloid plaque load or astrocytosis. Neuropharmacology 60(2-3): 223-34 (2011).
74. Alafuzoff I, Overmyer M, Helisalmi S, Soininen H. Lower Counts of Astroglia and Activated Microglia in Patients with Alzheimer's Disease with Regular Use of Non-Steroidal Anti-Inflammatory Drugs. J Alzheimers Dis 2(1): 37-46 (2000).
75. Halliday GM, Shepherd CE, McCann H, Reid WG, Grayson DA, Broe GA, et al. Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease. Arch Neurol 57(6): 831-6 (2000).
76. Sonnen JA, Larson EB, Walker RL, Haneuse S, Crane PK, Gray SL, et al. Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques. Neurology 75(13): 1203-10 (2010).
77. Chen HM, Wang L, D'Mello SR. A chemical compound commonly used to inhibit PKR, {8-(imidazol-4-ylmethylene)-6Hazolidino[5,4-g] benzothiazol-7-one}, protects neurons by inhibiting cyclin-dependent kinase. Eur J Neurosci 28(10): 2003-16 (2008).